Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telmisartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 6/20 | 0.98 |
| ▸ | PPARG | P37231 | 4/20 | 0.98 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | ACE | P12821 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telmisartan SCHEMBL1071821 | 1.00 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL4464 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29691699 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29414101 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29356790 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL2122886 | 0.99 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL998659 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL972356 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL3384004 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29113697 | 0.98 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993778-B2 | Process for manufacture of telmisartan | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-31 | — | — | US | claimed |
| EP-2322511-B1 | Process for the production of Telmisartan | BOEHRINGER INGELHEIM INT (DE) | 2013-07-31 | — | — | EP | claimed |
| US-20130137878-A1 | PROCESS FOR MANUFACTURE OF TELMISARTAN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | claimed |
| EP-1611108-B1 | METHOD FOR THE PRODUCTION OF TELMISARTAN | BOEHRINGER INGELHEIM INT (DE) | 2011-07-06 | — | — | EP | claimed |
| CN-100418953-C | Process for preparing telmisartan | BOEHRINGER INGELHEIM INT (DE) | 2008-09-17 | — | — | CN | claimed |
| US-7193089-B2 | Reacting 2-n-propyl-4-methyl-6-(1'-methylbenzimidazol-2'-yl)benzimidazole with phenyl-nitrile containing compound to obtain 2-cyano-4'-[2''-n-propyl-4''-methyl-6''-(1'''-methylbenzimidazol-2'''-yl)benzimidazol-1''-ylmethyl]biphenyl, which is hydrolyzed to form telmisartan | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-20 | — | — | US | claimed |
| CN-1768044-A | Process for preparing telmisartan | BOEHRINGER INGELHEIM INT (DE) | 2006-05-03 | — | — | CN | claimed |
| US-20040236113-A1 | Process for manufacture of telmisartan | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-25 | — | — | US | claimed |
| CN-116298309-B | High throughput cloning of paired bipartite immunoreceptor polynucleotides and uses thereof | 根路径基因组学公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116298309-A | High throughput cloning of paired bipartite immunoreceptor polynucleotides and uses thereof | 根路径基因组学公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116144706-A | High throughput cloning of paired bipartite immunoreceptor polynucleotides and uses thereof | 根路径基因组学公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-113933472-A | Dissolution medium for determining dissolution rate of telmisartan solid preparation and application thereof | 武汉武药科技有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-112585690-A | System and method for producing individualized individual unit doses containing a pharmaceutically active substance | 阿奎斯蒂弗医疗股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20050004193-A1 | Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| US-20040259925-A1 | Pharmaceutical compositions and methds for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-23 | — | — | US | disclosed |
| US-20040236113-A1 | Process for manufacture of telmisartan | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040162327-A1 | Crystalline form of telmisartan sodium | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-19 | — | — | US | disclosed |
| US-6737432-B2 | 4'-(2-N-PROPYL-4-METHYL-6-(1-METHYL-BENZIMIDAZOL-2-YL)BENZIMID AZOL-1-YLMETHYL)BIPHENYL-2-CARBOXYLIC ACID SODIUM; ANGIOTENSIN ANTAGONISTS; MELTING POINT OF 240-250 DEGREES CELSIUS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-05-18 | — | — | US | disclosed |
| US-20030130331-A1 | Crystalline form of telmisartan sodium | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130331-A1 | Crystalline form of telmisartan sodium | REN, AGT, TTR | AGTR1 4/4885PPARG 765/4885AGTR2 6/4885 |
| US-20050004193-A1 | Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases | REN, ACE, TTR | AGTR1 11/4885PPARG 264/4885AGTR2 13/4885 |
| US-20130137878-A1 | PROCESS FOR MANUFACTURE OF TELMISARTAN | REN, ACE, AGT | AGTR1 5/4885PPARG 2976/4885AGTR2 9/4885 |
| US-20040162327-A1 | Crystalline form of telmisartan sodium | REN, AGT, TTR | AGTR1 4/4885PPARG 765/4885AGTR2 6/4885 |
| US-20040236113-A1 | Process for manufacture of telmisartan | REN, AGT, ACE | AGTR1 4/4885PPARG 4059/4885AGTR2 17/4885 |
| US-20040259925-A1 | Pharmaceutical compositions and methds for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | REN, AGTR2, ACE2 | AGTR1 4/4885PPARG 926/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.